

Details of Q2 FY24 Quarterly Report, Appendix 4C & Webinar

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) will release its Q2 FY24 Quarterly Activities Report & Appendix 4C on Tuesday, 30 January 2024.

The Company will host an investor webinar with CEO Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro at 10:00am AEST / 11:00am AEDT on Tuesday, 30 January 2024.

Presenting: CEO, Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro

Time: 10:00am AEST / 11:00am AEDT on Tuesday, 30 January 2024

To register for the session and for more information on the conference click on the below link:

[Microba Q2 FY24 Investor Webinar Registration](#)

Investors can submit questions prior to the webinar investor@microba.com or do so via the Q&A functions on Zoom during the webinar.

This announcement has been authorised for release by the Chairman and CEO.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Investor / Media Relations

E: investor@microba.com

W: <https://ir.microba.com/>

[Join our Investor Mailing List](#)

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.